Have synchronous primary endometrial cancer
Bilateral synchronous tumors with inheritable forms of RCC including von Hippel-Lindau
Synchronous bilateral breast cancer at the time of diagnosis
Patients with synchronous bilateral invasive disease are eligible as long as all the lesions assessed for HER on both sides are negative
Synchronous bilateral breast cancer at the time of diagnosis
Synchronous primaries outside of the oropharynx and larynx
T tumors, known metastatic disease, recurrent disease, inflammatory breast cancer, multicentric disease, and/or synchronous bilateral breast cancer
Synchronous bilateral invasive or non-invasive breast cancer
Bilateral synchronous breast cancer
Complete preoperative colonoscopy demonstrating no synchronous colon cancer
Patients with known synchronous distant metastatic disease
Patients with bilateral synchronous renal masses
Synchronous bilateral invasive or non-invasive breast cancer
Synchronous cancer.
Synchronous colon cancer
Synchronous bilateral invasive or non-invasive breast cancer
Synchronous bilateral invasive breast cancer
Patients with synchronous colon cancers are eligible and staging for stratification will be based on higher N stage of the more advanced primary tumor; however, patients with synchronous colon and rectal primary tumors are not eligible
Operable tumor measuring >= . cm in maximal diameter\r\n* Any nodal status\r\n* Multifocal and multicentric disease is permitted\r\n* Synchronous bilateral invasive breast cancer is permitted\r\n* The tumor should be more than  mm from the skin
Patients may have synchronous endometrial and ovarian cancer primaries
Participants with synchronous bilateral invasive disease are eligible only if both lesions are HER-positive
Patients with synchronous bilateral breast cancers are eligible if at least one of the tumors is HER-positive
Patients with synchronous primaries are included
Patients with an obstructive synchronous colorectal tumor requiring up-front surgery or chemoradiation
Participants with bilateral synchronous or metachronous disease (DCIS, LCIS, ADH, ALH) are eligible
synchronous tumors
Patients with synchronous bilateral breast cancers